CorMedix Inc. experienced a significant price drop of 29.27%, hitting a 20-day low. This decline comes as the Nasdaq-100 is down 0.53%, indicating a challenging market environment.
The drop in CorMedix's stock price is attributed to sector rotation, despite the company's recent leadership changes and strategic appointments aimed at enhancing its market position. CEO Joseph Todisco's new role as Chairman and the appointment of Mike Seckler as Chief Commercial Officer are expected to drive the company's strategic development forward, particularly with the upcoming Phase III study results for REZZAYO anticipated in Q2 2026.
This leadership stability and product portfolio expansion could potentially strengthen CorMedix's competitiveness in the biopharmaceutical sector. However, the current market conditions and the stock's performance suggest that investors are cautious, leading to the observed decline.
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17.00 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast CRMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRMD is 17.00 USD with a low forecast of 14.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.750
Low
14.00
Averages
17.00
High
22.00
Current: 7.750
Low
14.00
Averages
17.00
High
22.00
H.C. Wainwright
Buy
downgrade
$18 -> $13
2026-01-23
Reason
H.C. Wainwright
Price Target
$18 -> $13
AI Analysis
2026-01-23
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on CorMedix to $13 from $18 and keeps a Buy rating on the shares. The firm says expectations have been reset following the updated 2026-2027 DefenCath guidance. CorMedix has entered the next phase of the story where clinical execution now matters more than commercial execution, the analyst tells investors in a research note.
RBC Capital
Outperform -> NULL
downgrade
$22 -> $13
2026-01-21
Reason
RBC Capital
Price Target
$22 -> $13
2026-01-21
downgrade
Outperform -> NULL
Reason
RBC Capital lowered the firm's price target on CorMedix to $13 from $22 and keeps an Outperform rating on the shares. The firm updated models for several biotech companies after meeting with managements.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRMD
Unlock Now
Truist
Buy
maintain
$20 -> $16
2026-01-08
Reason
Truist
Price Target
$20 -> $16
2026-01-08
maintain
Buy
Reason
Truist lowered the firm's price target on CorMedix to $16 from $20 and keeps a Buy rating on the shares after the company introduced a FY26 revenue guidance roughly 40% below the Street and 2027 DefenCath revenue guidance at roughly half the firm's initial estimate. This marks a significantly greater tail off for DefenCath than the firm and Wall Street have factored, the analyst tells investors in a research note. The firm added that it expects to hear more from the company at an upcoming Investor day on February 10.
H.C. Wainwright
Brandon Folkes
Buy
maintain
$17 -> $18
2025-11-13
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$17 -> $18
2025-11-13
maintain
Buy
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on CorMedix to $18 from $17 and keeps a Buy rating on the shares post the Q3 report. With the acquisition of Melinta now closed, CorMedix has a more diversified business going into 2026, the analyst tells investors in a research note.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
